Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
SNY
Strong BuyAPPROVESanofi · Healthcare · France · $107.4B · Avg Vol: $132M/d
This is the US line of Sanofi, which generates large free cash flow from its immunology franchise and vaccines business, funds a well-covered dividend and buybacks, and screens cheap on value (V78). The 2.8% consensus trim is modest. Nothing adverse is known on accounting, solvency or governance beyond long-disclosed litigation matters.
COMPANY DESCRIPTION
Sanofi is a global biopharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad range of healthcare solutions, encompassing prescription drugs, vaccines, and consumer healthcare products. Its significant competitive moat stems from a highly diversified portfolio of patented drugs and vaccines, strong global R&D capabilities, and extensive commercial reach across multiple therapeutic areas. Sanofi is a leading multinational pharmaceutical firm, particularly prominent in vaccine production and innovation in rare diseases and immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 47.0B | 48.2B | 51.3B | 54.1B | 4.8% | 57.1B | 59.1B | 62.9B | 7.8% |
| EPS | 3.11 | 2.50 | 2.66 | 3.71 | 6.0% | 1.89 | 3.96 | 4.27 | 7.3% |
| Shares | 1.3B | 1.3B | 1.3B | 1.2B | -4.2% | — | — | — | — |
| Debt | 24.6B | 21.3B | 20.7B | 23.6B | -1.4% | 27.5B | — | — | — |
| Equity | 86.7B | 85.8B | 89.8B | 82.7B | -1.5% | — | — | — | — |
| Op CF | 12.2B | 11.9B | 10.5B | 12.5B | 0.7% | 13.8B | — | — | — |
| Inv CF | -2.4B | -7.2B | -5.1B | -2.8B | — | — | — | — | — |
| Fin CF | -6.7B | -9.3B | -6.7B | -9.5B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SNY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SNY | Sanofi(you) | $107.4B | 96 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $136.0B | 99 | Strong Buy |
| GSK.L | GSK plc | $100.5B | 87 | Strong Buy |
| PFIZ34.SA | Pfizer Inc. | $161.7B | 93 | Strong Buy |
| NVON.MX | Novo Nordisk A/S | $207.3B | 95 | Strong Buy |
| AMG.DE | Amgen Inc. | $238.5B | 93 | Strong Buy |
| GILD.MX | Gilead Sciences, Inc. | $181.0B | 85 | Strong Buy |
| 4578.T | Otsuka Holdings Co., Ltd. | $40.0B | 94 | Strong Buy |
| BAYN.DE | Bayer Aktiengesellschaft | $55.6B | 81 | Strong Buy |
| 4503.T | Astellas Pharma Inc. | $26.6B | 98 | Strong Buy |
Peer medians: ROE 1.9% · P/E 24.0x · Gross margin 52.1%